Third dose, Son: “Ready for those who have received Johnson & Johnson vaccine”

Third dose covid vaccine for Johnson & Johnson recipients. “These insights are to the attention of the Ministry of Health, Aifa and the Aifa technical-scientific committee” said General Francesco Paolo Figliuolo, extraordinary commissioner for the Covid emergency, on the sidelines of a visit to the Meyer pediatric hospital in Florence , he replied to reporters who asked him the timing of the third dose. “When they give us indications, we will be ready for any kind of indication: the organization is there and the doses too.” As for the Omicron variant, Johnson & Johnson, explains the same company, will evaluate its anti-Covid vaccine. and to do so, it is testing the blood serum of participants in the completed and ongoing booster studies to verify neutralizing activity against the new mutant. At the same time, the US company is working on a specific vaccine against the Omicron variant and will carry it forward as needed. Since the emergence of the Covid pandemic, the note reads, “Johnson & Johnson has closely monitored the new emerging variants of Covid-19. In collaboration with academic groups in South Africa and around the world, the company evaluated the effectiveness of its vaccine for several variants, including the new Omicron variant which is spreading rapidly. Omicron, points out Mathai Mammen, Global Head of Janssen Research & Development, J&J, “highlights the importance of continuous surveillance, testing and vaccinations to prevent hospitalizations and deaths from Covid. We remain confident in the robust humoral and cell-mediated immune responses generated by the Johnson & Johnson’s vaccine against Covid, demonstrated by the duration and breadth of protection against the variants found so far in clinical trials “. But, added the expert,” we will not limit ourselves to this. Building on our long-standing collaboration With scientists in the field in South Africa and ongoing clinical practice efficacy studies with Johnson & Johnson’s Covid vaccine, we will work together to generate new data on Omicron. In parallel, we have begun work to design and develop a new vaccine against Omicron and we will rapidly move it forward in clinical trials if necessary. “